Get the Stockscreener App
35.38
1.93%
0.67
Indivior Pharmaceuticals Inc stock is traded at $35.38, with a volume of 1.96M.
It is up +1.93% in the last 24 hours and down -0.98% over the past month.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease.
See More
Previous Close:
$34.71
Open:
$34.63
24h Volume:
1.96M
Relative Volume:
0.79
Market Cap:
$4.42B
Revenue:
$1.12B
Net Income/Loss:
$5.00M
P/E Ratio:
3,538.00
EPS:
0.01
Net Cash Flow:
$-383.00M
1W Performance:
+7.31%
1M Performance:
-0.98%
6M Performance:
+103.33%
1Y Performance:
+190.00%
1-Day Range:
$34.31
$35.43
1-Week Range:
$33.49
$35.47
52-Week Range:
$7.62
$38.00
Indivior Pharmaceuticals Inc Stock (INDV) Company Profile
Name
Indivior Pharmaceuticals Inc
Sector
Phone
804-379-1090
Address
234 BATH ROAD, SLOUGH, BERKSHIRE
Compare INDV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INDV
Indivior Pharmaceuticals Inc
|
35.38 | 4.34B | 1.12B | 5.00M | -383.00M | 0.01 |
|
ZTS
Zoetis Inc
|
124.82 | 53.64B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.23 | 54.24B | 29.62B | 260.04M | 5.51B | 0.0787 |
|
HLN
Haleon Plc Adr
|
10.47 | 45.87B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.08 | 37.94B | 17.39B | 1.43B | 774.28M | 1.219 |
|
UTHR
United Therapeutics Corp
|
469.49 | 20.14B | 3.13B | 1.27B | 1.12B | 26.39 |
Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Initiated | H.C. Wainwright | Buy |
| Jul-22-25 | Resumed | Jefferies | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-23-24 | Initiated | Piper Sandler | Overweight |
| Apr-03-24 | Initiated | Craig Hallum | Buy |
| Jul-13-23 | Initiated | Northland Capital | Outperform |
View All
Indivior Pharmaceuticals Inc Stock (INDV) Latest News
Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ - The Manila Times
Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on ... - Caledonian Record
Indivior’s Stock Under Pressure: Can the Addiction-Treatment Specialist Regain Investor Trust? - AD HOC NEWS
INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) Presents a High-Growth Momentum Breakout Setup - Chartmill
Will Indivior’s (INDV) US Headquarters Shift and Larger ESOP Shelf Reshape Its Corporate Narrative? - simplywall.st
Indivior completes redomiciliation from UK to US By Investing.com - Investing.com Nigeria
Aug PreEarnings: Is Indivior PLC vulnerable to short sellersQuarterly Market Review & Growth Focused Stock Reports - baoquankhu1.vn
Indivior announces completion of redomiciliation to U.S. - TipRanks
Indivior (INDV) Completes Move from UK to US, Listed on Nasdaq - GuruFocus
Indivior Completes U.S. Domestication and Governance Realignment - TipRanks
Indivior Announces Completion of Redomiciliation to the United States - The Manila Times
Indivior completes redomiciliation from UK to US - Investing.com
Indivior Signs Note Purchase Agreement Amendment With Piper Sandler Finance - TradingView
Indivior PLC: Can a Focused Addiction-Treatment Portfolio Power the Next Wave of Growth? - AD HOC NEWS
Is Indivior PLC forming higher highs and higher lowsJuly 2025 Macro Moves & Weekly Hot Stock Watchlists - mfd.ru
(INDV) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Indivior’s 2026 Revenue Guidance Tightens Expectations Might Change The Case For Investing In Indivior (INDV) - Yahoo Finance
Aug Selloffs: Can Indivior PLC stock outperform in a bear marketJuly 2025 Technicals & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Indivior PLC: Can a Focused Addiction-Treatment Specialist Win the Next Decade of Mental Health Phar - AD HOC NEWS
Grail and Indivior PLC come out on top in healthcare quant picks ahead of Q4 earnings - MSN
Market Wrap: Will WNEB outperform small cap indexes2025 Sector Review & Trade Opportunity Analysis - baoquankhu1.vn
Indivior (NASDAQ:INDV) Downgraded to "Hold" Rating by Zacks Research - MarketBeat
Indivior PLC: How a Specialist Addiction Franchise Is Quietly Rebuilding a Global Pharma Contender - AD HOC NEWS
Indivior (INDV) Price Target Increased by 13.21% to 43.71 - Nasdaq
Q1 Earnings Forecast for Indivior Issued By HC Wainwright - MarketBeat
Portfolio Update: Is now the right time to enter Indivior PLCJuly 2025 Chart Watch & Accurate Entry/Exit Alerts - baoquankhu1.vn
Indivior PLC (INDV) Stock Analysis: Exploring a 24% Upside Potential in the Healthcare Sector - DirectorsTalk Interviews
Aug Setups: Does Indivior PLC stock trade at a discount to peersMarket Activity Summary & Safe Capital Growth Tips - Bộ Nội Vụ
Risks Report: Will Indivior PLC stock remain a Wall Street favorite2025 Technical Patterns & Free Real-Time Volume Trigger Notifications - Bộ Nội Vụ
Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes - Finviz
HC Wainwright Estimates Indivior's Q2 Earnings (NASDAQ:INDV) - MarketBeat
51,426 Shares in Indivior PLC $INDV Purchased by KLP Kapitalforvaltning AS - MarketBeat
Volume Recap: Is Indivior PLC forming higher highs and higher lows2025 Market Sentiment & Verified Entry Point Signals - baoquankhu1.vn
TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug - Finviz
Take the Zacks Approach to Beat the Markets: Indivior, FIGS & Ulta Beauty in Focus - Yahoo Finance
Indivior stock price target raised to $48 from $35 at H.C. Wainwright - Investing.com Nigeria
INDV: Analyst Raises Price Target to $48.00, Maintains Buy Ratin - GuruFocus
Naloxone Market Is Going to Boom |EMERGENT, Indivior PLC, Akorn, Inc - openPR.com
Indivior PLC (INDV) Announces Full-Year 2026 Financial Guidance - Finviz
Indivior (NasdaqGS:INDV) Valuation Check After Strong Long Term Returns And Recent Price Consolidation - Yahoo Finance
Indivior PLCOrdinary Shares (NQ: INDV - FinancialContent
Indivior forecasts 11% SUBLOCADE growth, 35% EBITDA increase for 2026 By Investing.com - Investing.com Nigeria
Craig-Hallum raises Indivior stock price target to $50 on strong 2026 outlook - Investing.com Nigeria
Aug Closing: Why hedge funds are buying Indivior PLC stockWall Street Watch & Safe Entry Trade Signal Reports - moha.gov.vn
Can Indivior PLC stock double in next 5 years2025 Volume Leaders & Safe Entry Point Alerts - ulpravda.ru
Why Indivior PLC (2IVB) stock is a strong analyst pickWeekly Risk Summary & Safe Entry Point Identification - ulpravda.ru
Why retail investors pile into Indivior PLC stockJuly 2025 Momentum & Fast Moving Market Watchlists - ulpravda.ru
Is Indivior PLC stock a top pick in earnings season2025 Macro Impact & Fast Exit Strategy with Risk Control - ulpravda.ru
What margin trends mean for Indivior PLC stockWeekly Trade Report & Real-Time Chart Pattern Alerts - ulpravda.ru
GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug - Finviz
Published on: 2026-01-08 20:56:58 - ulpravda.ru
Indivior Pharmaceuticals Inc Stock (INDV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Indivior Pharmaceuticals Inc Stock (INDV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Humphreys Keith | Director |
Jan 05 '26 |
Buy |
35.39 |
775 |
27,429 |
5,802 |
| NINIVAGGI DANIEL A | Director |
Jan 05 '26 |
Buy |
35.39 |
775 |
27,429 |
16,923 |
| Stejbach Mark | Director |
Jan 05 '26 |
Buy |
35.39 |
775 |
27,429 |
16,847 |
| Wheadon David E. | Director |
Jan 05 '26 |
Buy |
35.39 |
1,771 |
62,680 |
14,395 |
1.13%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):